Merit Cudkowicz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11882097/publications.pdf

Version: 2024-02-01

66 papers	4,865 citations	101543 36 h-index	114465 63 g-index
68 all docs	68 docs citations	68 times ranked	6230 citing authors

#	Article	IF	Citations
1	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
2	Phase 1â€“2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 2020, 383, 109-119.	27.0	354
3	Increased oxidative damage to DNA in ALS patients. Free Radical Biology and Medicine, 2000, 29, 652-658.	2.9	286
4	Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet, The, 2014, 383, 2065-2072.	13.7	233
5	The PRO-ACT database. Neurology, 2014, 83, 1719-1725.	1.1	222
6	Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nature Biotechnology, 2015, 33, 51-57.	17.5	178
7	Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2010, 9, 481-488.	10.2	177
8	Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. Journal of Clinical Investigation, 2018, 128, 3558-3567.	8.2	171
9	The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nature Medicine, 2011, 17, 1652-1656.	30.7	166
10	Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2021, 17, 104-118.	10.1	152
11	Vitamin E intake and risk of amyotrophic lateral sclerosis. Annals of Neurology, 2005, 57, 104-110.	5.3	143
12	Transplantation of spinal cordâ€“derived neural stem cells for ALS. Neurology, 2016, 87, 392-400.	1.1	127
13	Final Results of the RHAPSODY Trial: A Multiâ€Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3Aâ€APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Annals of Neurology, 2019, 85, 125-136.	5.3	113
14	A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology, 2017, 88, 152-159.	1.1	104
15	Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology, 2018, 90, e565-e574.	1.1	99
16	Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology, 2017, 89, 2495-2502.	1.1	97
17	Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurology, The, 2011, 10, 481-490.	10.2	96
18	SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy. JAMA Neurology, 2013, 70, 201.	9.0	93

#	Article	IF	Citations
19	Galectin-3 Is a Candidate Biomarker for Amyotrophic Lateral Sclerosis: Discovery by a Proteomics Approach. Journal of Proteome Research, 2010, 9, 5133-5141.	3.7	88
20	Randomized phase 2 trial of NP001, a novel immune regulator. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e100.	6.0	83
21	Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 1-10.	2.1	81
22	Depression in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 109-112.	2.1	80
23	How common are ALS plateaus and reversals?. Neurology, 2016, 86, 808-812.	1.1	78
24	Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. Neurotherapeutics, 2017, 14, 762-772.	4.4	73
25	ALS Drug Development: Reflections from the Past and a Way Forward. Neurotherapeutics, 2008, 5, 516-527.	4.4	71
26	Measures and markers in Amyotrophic Lateral Sclerosis. NeuroRx, 2004, 1, 273-283.	6.0	63
27	Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle and Nerve, 2020, 62, 156-166.	2.2	60
28	Outcome measures in amyotrophic lateral sclerosis clinical trials. Clinical Investigation, 2014, 4, 605-618.	0.0	50
29	Arimoclomol: a potential therapy under development for ALS. Expert Opinion on Investigational Drugs, 2009, 18, 1907-1918.	4.1	49
30	Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach. Scientific Reports, 2019, 9, 690.	3.3	46
31	Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial. PLoS ONE, 2014, 9, e97803.	2.5	45
32	Longâ€term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Annals of Clinical and Translational Neurology, 2018, 5, 730-740.	3.7	44
33	Biomarkers for amyotrophic lateral sclerosis. Expert Review of Molecular Diagnostics, 2006, 6, 387-398.	3.1	42
34	Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?. Neurotherapeutics, 2015, 12, 417-423.	4.4	41
35	Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. Annals of Neurology, 2022, 91, 165-175.	5.3	41
36	Defining Survival as an Outcome Measure in Amyotrophic Lateral Sclerosis. Archives of Neurology, 2009, 66, 758-61.	4.5	39

#	Article	IF	Citations
37	Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Openâ€Access ALS clinical trials database. Muscle and Nerve, 2018, 57, 430-434.	2.2	39
38	Quantitative strength testing in ALS clinical trials. Neurology, 2016, 87, 617-624.	1.1	37
39	Design of phase II ALS clinical trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 16-23.	2.1	34
40	Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1522-1533.	3.7	31
41	Therapy development for ALS: Lessons learned and path forward. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 131-140.	2.1	30
42	A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 508-513.	2.1	30
43	Preâ€morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Muscle and Nerve, 2015, 52, 339-343.	2.2	25
44	Risk factors for suicidality in Huntington disease. Neurology, 2019, 92, e1643-e1651.	1.1	22
45	Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection. Stroke, 2016, 47, 2979-2985.	2.0	20
46	Enhancing clinical trials in neurodegenerative disorders. Current Opinion in Neurology, 2012, 25, 735-742.	3.6	17
47	Primary Lateral Sclerosis and Early Upper Motor Neuron Disease. Journal of Clinical Neuromuscular Disease, 2016, 17, 99-105.	0.7	17
48	Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS). Journal of Neurology & Neurophysiology, 2017, 08, .	0.1	17
49	Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis. EBioMedicine, 2018, 33, 169-184.	6.1	17
50	Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients. Frontiers in Neurology, 2020, 11, 590573.	2.4	16
51	Gold Coast diagnostic criteria: Implications for <scp>ALS</scp> diagnosis and clinical trial enrollment. Muscle and Nerve, 2021, 64, 532-537.	2.2	16
52	Phase <scp>2B</scp> randomized controlled trial of <scp>NP001</scp> in amyotrophic lateral sclerosis: Preâ€specified and post hoc analyses. Muscle and Nerve, 2022, 66, 39-49.	2.2	16
53	Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS. BMC Neurology, 2019, 19, 104.	1.8	13
54	Amyotrophic Lateral Sclerosis: An Emerging Era of Collaborative Gene Discovery. PLoS ONE, 2007, 2, e1254.	2.5	13

#	Article	IF	Citations
55	Opportunities for improving therapy development in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 169-173.	1.7	12
56	Maximum voluntary isometric contraction (MVIC). Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 84-85.	1.2	11
57	Proposed BioRepository platform solution for the ALS research community. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 11-16.	2.1	11
58	Seven-Year Experience From the National Institute of Neurological Disorders and Strokeâ€“Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurology, 2020, 77, 755.	9.0	6
59	Disease Burden in Upper Motor Neuron Syndromes. Journal of Clinical Neuromuscular Disease, 2014, 16, 104-105.	0.7	5
60	ALSUntangled #63: ketogenic diets. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 159-163.	1.7	3
61	ALS/SURV: a modification of the CAFS statistic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 576-583.	1.7	2
62	Would riluzole be efficacious in the new ALS trial design? â€“ Authors' reply. Lancet Neurology, The, 2010, 9, 950-951.	10.2	1
63	Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS). Neurology: Clinical Practice, 2021, 11, e472-e479.	1.6	1
64	Baseline Variables Associated with Functional Decline in 2CARE, A Randomized Clinical Trial in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2020, 9, 47-58.	1.9	0
65	Measures and markers in Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2004, 1, 273-283.	4.4	0
66	Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design. Neurology: Clinical Practice, 2021, 11, e472-e479.	1.6	0